Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin.
Influenza virus remains a significant health and social concern in part because of newly emerging strains, such as avian H5N1 virus. We have developed a prototype H5N1 vaccine using a recombinant, replication-competent Adenovirus serotype 4 (Ad4) vector, derived from the U.S. military Ad4 vaccine st...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3281928?pdf=render |
| _version_ | 1828769943465754624 |
|---|---|
| author | Jeff Alexander Simone Ward Jason Mendy Darly J Manayani Peggy Farness Jenny B Avanzini Ben Guenther Fermin Garduno Lily Jow Victoria Snarsky Glenn Ishioka Xin Dong Lo Vang Mark J Newman Tim Mayall |
| author_facet | Jeff Alexander Simone Ward Jason Mendy Darly J Manayani Peggy Farness Jenny B Avanzini Ben Guenther Fermin Garduno Lily Jow Victoria Snarsky Glenn Ishioka Xin Dong Lo Vang Mark J Newman Tim Mayall |
| author_sort | Jeff Alexander |
| collection | DOAJ |
| description | Influenza virus remains a significant health and social concern in part because of newly emerging strains, such as avian H5N1 virus. We have developed a prototype H5N1 vaccine using a recombinant, replication-competent Adenovirus serotype 4 (Ad4) vector, derived from the U.S. military Ad4 vaccine strain, to express the hemagglutinin (HA) gene from A/Vietnam/1194/2004 influenza virus (Ad4-H5-Vtn). Our hypothesis is that a mucosally-delivered replicating Ad4-H5-Vtn recombinant vector will be safe and induce protective immunity against H5N1 influenza virus infection and disease pathogenesis.The Ad4-H5-Vtn vaccine was designed with a partial deletion of the E3 region of Ad4 to accommodate the influenza HA gene. Replication and growth kinetics of the vaccine virus in multiple human cell lines indicated that the vaccine virus is attenuated relative to the wild type virus. Expression of the HA transgene in infected cells was documented by flow cytometry, western blot analysis and induction of HA-specific antibody and cellular immune responses in mice. Of particular note, mice immunized intranasally with the Ad4-H5-Vtn vaccine were protected against lethal H5N1 reassortant viral challenge even in the presence of pre-existing immunity to the Ad4 wild type virus.Several non-clinical attributes of this vaccine including safety, induction of HA-specific humoral and cellular immunity, and efficacy were demonstrated using an animal model to support Phase 1 clinical trial evaluation of this new vaccine. |
| first_indexed | 2024-12-11T13:57:18Z |
| format | Article |
| id | doaj.art-942bade51b5e4d14aa02fb115e1fab4b |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T13:57:18Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-942bade51b5e4d14aa02fb115e1fab4b2022-12-22T01:03:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0172e3117710.1371/journal.pone.0031177Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin.Jeff AlexanderSimone WardJason MendyDarly J ManayaniPeggy FarnessJenny B AvanziniBen GuentherFermin GardunoLily JowVictoria SnarskyGlenn IshiokaXin DongLo VangMark J NewmanTim MayallInfluenza virus remains a significant health and social concern in part because of newly emerging strains, such as avian H5N1 virus. We have developed a prototype H5N1 vaccine using a recombinant, replication-competent Adenovirus serotype 4 (Ad4) vector, derived from the U.S. military Ad4 vaccine strain, to express the hemagglutinin (HA) gene from A/Vietnam/1194/2004 influenza virus (Ad4-H5-Vtn). Our hypothesis is that a mucosally-delivered replicating Ad4-H5-Vtn recombinant vector will be safe and induce protective immunity against H5N1 influenza virus infection and disease pathogenesis.The Ad4-H5-Vtn vaccine was designed with a partial deletion of the E3 region of Ad4 to accommodate the influenza HA gene. Replication and growth kinetics of the vaccine virus in multiple human cell lines indicated that the vaccine virus is attenuated relative to the wild type virus. Expression of the HA transgene in infected cells was documented by flow cytometry, western blot analysis and induction of HA-specific antibody and cellular immune responses in mice. Of particular note, mice immunized intranasally with the Ad4-H5-Vtn vaccine were protected against lethal H5N1 reassortant viral challenge even in the presence of pre-existing immunity to the Ad4 wild type virus.Several non-clinical attributes of this vaccine including safety, induction of HA-specific humoral and cellular immunity, and efficacy were demonstrated using an animal model to support Phase 1 clinical trial evaluation of this new vaccine.http://europepmc.org/articles/PMC3281928?pdf=render |
| spellingShingle | Jeff Alexander Simone Ward Jason Mendy Darly J Manayani Peggy Farness Jenny B Avanzini Ben Guenther Fermin Garduno Lily Jow Victoria Snarsky Glenn Ishioka Xin Dong Lo Vang Mark J Newman Tim Mayall Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. PLoS ONE |
| title | Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. |
| title_full | Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. |
| title_fullStr | Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. |
| title_full_unstemmed | Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. |
| title_short | Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin. |
| title_sort | pre clinical evaluation of a replication competent recombinant adenovirus serotype 4 vaccine expressing influenza h5 hemagglutinin |
| url | http://europepmc.org/articles/PMC3281928?pdf=render |
| work_keys_str_mv | AT jeffalexander preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT simoneward preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT jasonmendy preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT darlyjmanayani preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT peggyfarness preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT jennybavanzini preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT benguenther preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT fermingarduno preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT lilyjow preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT victoriasnarsky preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT glennishioka preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT xindong preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT lovang preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT markjnewman preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin AT timmayall preclinicalevaluationofareplicationcompetentrecombinantadenovirusserotype4vaccineexpressinginfluenzah5hemagglutinin |